Blood soluble Fas concentrations and ischemic stroke patient mortality.
cerebral infarction
mortality
patients
sFas
Journal
Expert review of molecular diagnostics
ISSN: 1744-8352
Titre abrégé: Expert Rev Mol Diagn
Pays: England
ID NLM: 101120777
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
pubmed:
10
1
2023
medline:
26
1
2023
entrez:
9
1
2023
Statut:
ppublish
Résumé
Fas is a major receptor for cell death by apoptosis. Higher blood concentrations of soluble Fas (sFas) have been reported in patients with ischemic stroke compared to control subjects. The aim of this study was to explore the existence or not of an association between blood sFas concentrations and mortality in patients with ischemic stroke. This study included patients admitted to Intensive Care Units with severe and malignant middle cerebral artery infarction (MCAI), defined as acute infarction, in more than 50% of this territory on computed tomography and less than 9 points on the Glasgow Coma Scale (GCS). Serum sFas levels were determined at the time of diagnosis of MMCAI. Non-surviving severe MMCAI patients (n = 27) showed lower platelet count (p = 0.004), higher serum sFas (p < 0.001), and lower GCS (p = 0.001) compared to surviving patients (n = 27). Multiple logistic regression found an association of serum sFas levels and mortality at 30 days (OR = 1.015; 95% CI = 1.002-1.027; p = 0.02) after control for CGS and platelet count. The main novelty of our study was the existence of an association between high blood sFas concentrations and mortality in patients with ischemic stroke.
Sections du résumé
BACKGROUND
UNASSIGNED
Fas is a major receptor for cell death by apoptosis. Higher blood concentrations of soluble Fas (sFas) have been reported in patients with ischemic stroke compared to control subjects. The aim of this study was to explore the existence or not of an association between blood sFas concentrations and mortality in patients with ischemic stroke.
METHODS
UNASSIGNED
This study included patients admitted to Intensive Care Units with severe and malignant middle cerebral artery infarction (MCAI), defined as acute infarction, in more than 50% of this territory on computed tomography and less than 9 points on the Glasgow Coma Scale (GCS). Serum sFas levels were determined at the time of diagnosis of MMCAI.
RESULTS
UNASSIGNED
Non-surviving severe MMCAI patients (n = 27) showed lower platelet count (p = 0.004), higher serum sFas (p < 0.001), and lower GCS (p = 0.001) compared to surviving patients (n = 27). Multiple logistic regression found an association of serum sFas levels and mortality at 30 days (OR = 1.015; 95% CI = 1.002-1.027; p = 0.02) after control for CGS and platelet count.
CONCLUSIONS
UNASSIGNED
The main novelty of our study was the existence of an association between high blood sFas concentrations and mortality in patients with ischemic stroke.
Identifiants
pubmed: 36621530
doi: 10.1080/14737159.2022.2165913
doi:
Substances chimiques
FAS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM